Date of event - estimated.The unique device identifier (udi) is unknown because the part and lot numbers were not provided.Implant date - estimated.The devices were not returned for analysis.A review of the lot history records and similar complaint reviews could not be performed as the part and lot information regarding the complaint devices were not provided.The reported patient effects of heart failure, atrial perforation, atrial fibrillation, hypertension, renal failure, cardiogenic shock, cerebrovascular accident, and transient ischemic attack as listed in the mitraclip system instructions for use, are known possible complications associated with mitraclip procedures.Based on the available information, a cause for the reported patient effects of heart failure, atrial perforation, atrial fibrillation, hypertension, renal failure, cardiogenic shock, cerebrovascular accident, and transient ischemic attack could not be determined.The reported hospitalization and additional therapy/non-surgical treatment were results of case-specific circumstances.There is no indication of a product quality issue with respect to manufacture, design or labeling.The patient deaths mentioned in b5 and in the article are filed under separate mfr report numbers.Literature title : risk of percutaneous iatrogenic atrial septal defect closure required shortly after transseptal mitral valve intervention.
|
This will be filed to report the serious injuries.It was reported through a research article identifying mitraclip that may be related to the following: patient deaths, heart failure, atrial perforation, atrial fibrillation, hypertension, renal failure, cardiogenic shock, stroke, ischemic attack, re-hospitalization, and medical intervention.Details are listed in the attached article, titled ¿risk of percutaneous iatrogenic atrial septal defect closure required shortly after transseptal mitral valve intervention.¿ please see article for additional information.
|